About CNM-Au8® Our lead drug candidate, CNM-Au8, is an oral suspension of clean-surfaced, catalytically-active gold nanocrystals. Resulting from a number of patented manufacturing breakthroughs, CNM-Au8 is currently in development as a disease-modifying treatment for Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson’s Disease. There have been over 1,000 patient years of CNM-Au8 exposure without identified safety … Continue reading About CNM-Au8®